血浆同型半胱氨酸与帕金森病痴呆的关系  

Relationship between plasma homocysteine and Parkinson′s disease with dementia

作　　者：潘宁丰[1,2] 叶民[3] 

机构地区：[1]南京医科大学,江苏省210029 [2]南京市市级机关医院神经内科 [3]南京医科大学附属南京明基医院神经内科

出　　处：《江苏医药》2014年第19期2278-2280,共3页Jiangsu Medical Journal

摘　　要：目的研究血浆同型半胱氨酸(Hcy)与帕金森病痴呆的关系以及恩他卡朋对左旋多巴诱导的高Hcy血症的治疗效果。方法抽取正常健康老人(A组,30例)、帕金森病非痴呆患者(B组,60例)和帕金森病痴呆患者(C组,60例)静脉血,采用酶循环法测定血浆Hcy浓度。B组、C组又分别均分为美多巴治疗组(B1组,30例;C1组,30例)和美多巴联合恩他卡朋治疗组(B2,30例;C2组,30例)。结果 B1、B2、C1和C2组血浆Hcy水平均高于A组[(18.03±0.99)μmol/L、(14.91±0.90)μmol/L、(24.05±1.46)μmol/L和(20.44±1.30)μmol/L vs.(9.26±0.81)μmol/L](P<0.01)。C组血浆Hcy水平高于B组(P<0.01);B1组血浆Hcy水平高于B2组,C1组Hcy水平高于C2组(P<0.01)。结论高Hcy血症可能是帕金森病痴呆的危险因素之一;恩他卡朋可以降低左旋多巴诱导的高Hcy血症。Objective To study the correlation between plasma homocysteine （Hcy） and Parkinson＇s disease with dementia and the efficacy of entacapone in the treatment of levedopa-induced hyperhomocysteinemia. Methods Plasma levels of Hcy were detected by enzymatic recycling method in healthy elder people（group A, 30 cases）, the patients with Parkinson＇ s disease without dementia （group B, 60 cases） and those with dementia（group C, 60 cases）. The patients in groups of B and C were subdivided into groups of B1 and Cl（treated with levedopa, 30 and 30 cases） and B2 and C2 （treated with levedopa and entacapone, 30 cases each）. Results Plasma levels of Hcy in groups of B1, B2,C1 and C2 were higher than those in group A[（18.03±0.99）/μmol/L, （14.91±0. 90） /μmol/L, （24. 05±1.46） μmol/L and （20. 44±1.30） μmol/L vs. （9.26±0. 81） μmol/L] （P〈0. 01）. Plasma level of Hcy was higher in group C than that in group B（P〈0. 01） ,which was higher in groups of B1 and C1 than that in groups of 132 and C2（P（0. 01）. Conclusion Hyperbomocysteinemia may be one of the risk factors for Parkinsonp s disease with dementia. Entacapone may reduce levodopa-induced hyperhomocysteinemia.

关 键 词：同型半胱氨酸 帕金森病 痴呆 

分 类 号：R742[医药卫生—神经病学与精神病学]